4D Molecular Therapeutics (FDMT) versus Its Rivals Head to Head Review

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare 4D Molecular Therapeutics to related businesses based on the strength of its institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Earnings & Valuation

This table compares 4D Molecular Therapeutics and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
4D Molecular Therapeutics $92.01 million -$140.11 million -4.37
4D Molecular Therapeutics Competitors $756.96 million $11.71 million -18.54

4D Molecular Therapeutics’ competitors have higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

4D Molecular Therapeutics has a beta of 2.92, suggesting that its stock price is 192% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics’ competitors have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Institutional & Insider Ownership

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares 4D Molecular Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
4D Molecular Therapeutics -208.57% -47.06% -40.05%
4D Molecular Therapeutics Competitors -12,224.09% -202.33% -31.23%

Analyst Recommendations

This is a summary of recent recommendations and price targets for 4D Molecular Therapeutics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4D Molecular Therapeutics 1 0 10 0 2.82
4D Molecular Therapeutics Competitors 9923 15317 45687 1603 2.54

4D Molecular Therapeutics presently has a consensus target price of $30.22, suggesting a potential upside of 156.38%. As a group, “Biotechnology” companies have a potential upside of 129.61%. Given 4D Molecular Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe 4D Molecular Therapeutics is more favorable than its competitors.

Summary

4D Molecular Therapeutics beats its competitors on 8 of the 13 factors compared.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, Inc. is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company’s proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.